Aphria (APHQF) was among the worst performers this year with a loss of 34% YTD (year-to-date), which was similar to companies (HMMJ) such as MedReleaf (MEDFF) and Supreme Cannabis (SPRWF). In March, the stock reached a peak of 14.76 Canadian dollars but closed at its lowest point in March at 13.42 Canadian dollars on March 22, 2018.
As of March 22, the consensus analyst mean rating on Aphria was 1.75, which remained unchanged from the previous month. As we can see in the above chart, three analysts continue to have a “strong buy” recommendation, while four analysts continue to have a “buy” recommendation on the stock for the next-12-month period.
Also, one analyst has maintained a “hold” recommendation and none of the analysts have a “sell” recommendation on the stock, which is similar to CannTrust (CNTTF).
Similar to how the analyst ratings on Aphria remained unchanged month-over-month in March, the consensus mean price target has also remained unchanged at 23.19 Canadian dollars and the median price target remained unchanged at 26 Canadian dollars.
Aphria closed at 13.4 Canadian dollars on March 22, which leaves a 72.8% upside on the stock when compared to the mean price target. Compared with the median price target, we see an upside of almost 94% on the stock.